Aerie Pharmaceuticals is a commercial-stage pharmaceutical company focused on discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Inspired by the vision of our co-founder, David L. Epstein, M.D. (1943-2014), then Chairman of the Department of Ophthalmology at Duke University, we have built a company committed to innovation in eye care.
Dr. Epstein collaborated with chemists to translate compound structures into clinical medications. Casey Kopczynski, Ph.D., a biotech start-up veteran, brought his business expertise to the company, and together they set out to bring a new class of medications to transform the glaucoma therapeutic area. Dr. Epstein challenged his colleagues to develop therapies directed at the diseased tissue, and it was this quest for a trabecular outflow drug that led to the discovery of the Rho Kinase inhibitor netarsudil (ROCKi). Aerie continues this legacy of discovery to find novel therapeutic treatments for eye diseases, including dry eye, retinal diseases, and ocular surface inflammation.
“The ideal therapeutic goal is the reversal of the basic defect...”
David L. Epstein, M.D.